Pomalyst Imnovid — Total Revenues
Bristol-Myers Squibb Pomalyst Imnovid — Total Revenues decreased by 4.7% to $675.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 24.8%, from $898.00M to $675.00M. Over 3 years (FY 2021 to FY 2024), Pomalyst Imnovid — Total Revenues shows relatively stable performance with a 2.1% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase in revenue suggests strong market penetration and sustained demand for the therapy, while a decrease may indicate increased generic competition, patent expirations, or shifts in clinical treatment guidelines.
Detailed definition
This metric represents the total global net sales generated from the Pomalyst/Imnovid product line, which is a key oncol...
Peer comparison
Comparable to revenue metrics for specific blockbuster oncology assets at peer pharmaceutical companies, often evaluated against the backdrop of patent cliffs and competitive biosimilar entry.
bmy_segment_pomalyst_imnovid_total_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $854.00M | $851.00M | $854.00M | $826.00M | $908.00M | $886.00M | $877.00M | $832.00M | $847.00M | $872.00M | $890.00M | $865.00M | $959.00M | $898.00M | $823.00M | $658.00M | $708.00M | $675.00M |
| QoQ Change | — | -0.4% | +0.4% | -3.3% | +9.9% | -2.4% | -1.0% | -5.1% | +1.8% | +3.0% | +2.1% | -2.8% | +10.9% | -6.4% | -8.4% | -20.0% | +7.6% | -4.7% |
| YoY Change | — | — | — | — | +6.3% | +4.1% | +2.7% | +0.7% | -6.7% | -1.6% | +1.5% | +4.0% | +13.2% | +3.0% | -7.5% | -23.9% | -26.2% | -24.8% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Bristol-Myers Squibb's pomalyst imnovid — total revenues?
- Bristol-Myers Squibb (BMY) reported pomalyst imnovid — total revenues of $675.00M in Q3 2025.
- How has Bristol-Myers Squibb's pomalyst imnovid — total revenues changed year-over-year?
- Bristol-Myers Squibb's pomalyst imnovid — total revenues decreased by 24.8% year-over-year, from $898.00M to $675.00M.
- What is the long-term trend for Bristol-Myers Squibb's pomalyst imnovid — total revenues?
- Over 3 years (2021 to 2024), Bristol-Myers Squibb's pomalyst imnovid — total revenues has grown at a 2.1% compound annual growth rate (CAGR), from $3.33B to $3.55B.
- What does pomalyst imnovid — total revenues mean?
- Total global revenue generated from the sale of the oncology drug Pomalyst/Imnovid.